Trial site
St. Vincent Frontier Cancer Center
Billings, Montana 59102, United StatesNot linked to an institution yet
- 12running trials
- 10closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 24 trials
- Phase 1/23 trials
- Phase 11 trial
- Status
- Active, not recruiting9 trials
- Completed7 trials
- Recruiting3 trials
- Terminated3 trials
- Lead sponsor
- Novartis Pharmaceuticals3 trials
- BeOne Medicines2 trials
- Loxo Oncology, Inc.2 trials
- Asahi Kasei Therapeutics, Inc.1 trial
- AVEO Pharmaceuticals, Inc.1 trial
- and 13 more
Running trials
Recruiting
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
NCT07288177· Phase 2· Genmab· Source
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784· Phase 3· Revolution Medicines, Inc.· Source
Contact: Revolution Medicines Study Director
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671· Phase 3· BeOne Medicines· Source
Contact: Study Director
Active, not recruiting
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370· Phase 1/2· BeiGene· Source
Active, not recruiting
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489· Phase 2· Shanghai Henlius Biotech· Source
Active, not recruiting
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
NCT05384587· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743· Phase 3· Loxo Oncology, Inc.· Source
Contact: Patrick Cobb (principal investigator)
Active, not recruiting
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
NCT05169567· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862· Phase 3· BeOne Medicines· Source
Active, not recruiting
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683· Phase 3· HUYABIO International, LLC.· Source
Active, not recruiting
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038· Phase 3· Loxo Oncology, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
NCT05605964· Phase 3· Sumitomo Pharma America, Inc.· Source
Terminated
Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
NCT05251727· Phase 1· Asahi Kasei Therapeutics, Inc.· Source
Completed
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
NCT04987203· Phase 3· AVEO Pharmaceuticals, Inc.· Source
Completed
XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
NCT04825288· Phase 1/2· XBiotech, Inc.· Source
Terminated
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
NCT03520686· Phase 3· ImmunityBio, Inc.· Source
Completed
Combination Study of SV-BR-1-GM With Retifanlimab
NCT03328026· Phase 1/2· BriaCell Therapeutics Corporation· Source
Completed
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
NCT03056755· Phase 2· Novartis Pharmaceuticals· Source
Completed
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
NCT02998528· Phase 3· Bristol-Myers Squibb· Source
Completed
Avelumab in First-line NSCLC (JAVELIN Lung 100)
NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Terminated
Connect® Myeloid Disease Registry
NCT01688011· Celgene· Source
Report an error